title: A current approach to statin intolerance.
abstract: Statins are the first-line pharmacotherapy for cholesterol reduction. Use of these drugs in large randomized clinical trials has consistently shown significant reductions in major vascular events, including death, myocardial infarction, stroke, and coronary revascularization. The updated guidelines for the treatment of high blood cholesterol from the American College of Cardiology/American Heart Association (ACC/AHA), will lead to an increase in the number of patients taking statins. Hence, the number of cases of statin intolerance may subsequently increase, emphasizing the need to understand and treat this important problem.
authors.affiliation: Leon H. Charney Division of Cardiology, NYU Langone Medical Center, New York, New York, USA.
authors.forename: R
authors.initials: R
authors.lastname: Tompkins
authors.affiliation: The Center for the Prevention of Cardiovascular Disease, Leon H. Charney Division of Cardiology, NYU-Langone Medical Center, New York, New York, USA.
authors.forename: A
authors.initials: A
authors.lastname: Schwartzbard
authors.affiliation: The Center for the Prevention of Cardiovascular Disease, Leon H. Charney Division of Cardiology, NYU-Langone Medical Center, New York, New York, USA.
authors.forename: E
authors.initials: E
authors.lastname: Gianos
authors.affiliation: The Center for the Prevention of Cardiovascular Disease, Leon H. Charney Division of Cardiology, NYU-Langone Medical Center, New York, New York, USA.
authors.forename: E
authors.initials: E
authors.lastname: Fisher
authors.affiliation: The Center for the Prevention of Cardiovascular Disease, Leon H. Charney Division of Cardiology, NYU-Langone Medical Center, New York, New York, USA.
authors.forename: H
authors.initials: H
authors.lastname: Weintraub
mesh_terms: D002784:Cholesterol / Q000378:metabolism; D003402:Creatine Kinase / Q000097:blood; D004347:Drug Interactions; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D027381:Liver-Specific Organic Anion Transporter 1; D063806:Myalgia / Q000139:chemically induced; D009220:Myositis / Q000139:chemically induced; D027361:Organic Anion Transporters / Q000235:genetics; D011110:Polymorphism, Genetic; D012206:Rhabdomyolysis / Q000139:chemically induced; D012307:Risk Factors; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000378:metabolism
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D027381:Liver-Specific Organic Anion Transporter 1; D027361:Organic Anion Transporters; C503999:SLCO1B1 protein, human; D014451:Ubiquinone; D002784:Cholesterol; D003402:Creatine Kinase; C024989:coenzyme Q10